Company intelligence / Profile preview
Mabpro
Bratislava, Bratislava region, Slovakiamabpro.sk ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mabpro is developing monoclonal antibody-based immunotherapies targeting CAIX for aggressive and hypoxic tumors. Its lead candidate, CA9hu-1, is in Phase 1 clinical trials for metastatic clear cell renal cell carcinoma. The company’s approach leverages the role of CAIX as a marker of tumor hypoxia and resistance to conventional therapies. No published clinical results are available yet.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed.
Beyond the preview
Go deeper on Mabpro.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mabpro.